Mode
Text Size
Log in / Sign up
N/A N=35

Clitoral Location in Relation to Sexual Function Using Pelvic Imaging

Female Sexual Dysfunction · Anorgasmia

Enrolled (actual)
35
Serious AEs
0.0%
Results posted
Dec 2014
Primary outcome: Primary: Clitoral Measurements Using Pelvic MRI — 51.3; 45.1; 29.4; 20.6 millimeters (mm)

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Adult · 18+ yrs
Sex
Female
Sponsor
TriHealth Inc.
Primary completion
Sep 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Clitoral Measurements Using Pelvic MRI
51.3; 45.1; 29.4; 20.6; 24.2; 28.3
SECONDARY
Free Testosterone
2.6; 2.5
SECONDARY
Total Testosterone
26.5; 33.0
SECONDARY
Free Androgen Index
1.3; 1.2
SECONDARY
Female Sexual Function Index (FSFI) Total Score
20.2; 31.6
SECONDARY
FSFI Desire
2.6; 4.8
SECONDARY
FSFI Arousal
3.2; 5.4
SECONDARY
FSFI Lubrication
4.0; 5.5
SECONDARY
FSFI Orgasm
1.9; 5.6
SECONDARY
FSFI Satisfaction
3.6; 4.8
SECONDARY
FSFI Pain
4.9; 5.5

Summary

Women who are unable to achieve orgasm compared to women who have normal orgasmic function may have different clitoral anatomy and different hormone levels. The investigators hypothesis is that women who have difficulty with orgasm may have a clitoris that is closer to the vagina and may have higher testosterone levels. Pelvic MRI will be used to observe whether clitoral measurements differ between women with normal orgasmic function vs. those with anorgasmia.

Eligibility Criteria

Inclusion Criteria

  • Premenopausal female aged 18-55 years
  • Sexually active (at least 1 heterosexual partner in the past 4 weeks)
  • Cases must have difficulty with orgasm or be anorgasmic
  • Controls must have normal sexual function

Exclusion Criteria

  • Not sexually active
  • Homosexual orientation
  • Postmenopausal
  • Stage >2 pelvic organ prolapse (POP-Q measurements beyond hymen)
  • Urinary incontinence with coitus limiting sexual activity
  • Severe vaginal atrophy
  • Pelvic pain/dyspareunia (
  • Currently pregnant
  • Depression being treated with SSRIs (depression alone or treatment of depression with non-SSRI medications is not an exclusion)
  • Currently taking testosterone supplements
  • History of sexual abuse
  • Large pelvic mass (benign or cancerous) impeding MRI measurements or grossly abnormal pelvic anatomy.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01195701). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search